Sarah Wilkes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sarah Wilkes has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Paul-Hugo Marie van der Kuy
Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, Netherlands
4 shared publications - Rianne Zaal
Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands
3 shared publications Alan Abdulla
Pharmacy, Erasmus Medical Centre, Rotterdam, The Netherlands
2 shared publications- Floor van Rosse
Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
2 shared publications - Jorie Versmissen
Department of Vascular Medicine and Pharmacology Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands
2 shared publications - A. Laura Nijstad
Pharmacy, Erasmus Medical Centre, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by BMJ in European Journal of Hospital Pharmacy
Digitising controlled substance accountability: implementation and use of a dashboard-based monitoring system in an university hospital
Objectives Opioids are the cornerstone of severe pain management but they have a strong potential for abuse. To mitigate this risk, hospitals are required to track and account for these controlled substances (CS). Despite widespread adoption of electronic medication administration records (eMAR), nurses also performed paper-based registrations for CS. We hypothesised that a validated dashboard combining dispensing and eMAR data could be implemented for CS accountability. This study describes trends in accountability of dispenses through administrations before, during and after implementation of the dashboard that replaced the paper-based process. Furthermore, we describe its application in analysing signalled discrepancies. Methods This implementation study was performed in a university hospital. The dashboard was developed by a multidisciplinary team consisting of hospital pharmacists, pharmacy technicians, nurses and data analysts. Data from 2018 to 2024 were compared in three periods: prior implementation (2018–2019), during implementation (2020–2022) and after implementation (2023–2024) of the dashboard. Monitored CS medications were limited to oral solids. The data for dispenses and administrations were validated against the electronic health record (EHR) and electronic delta calculations were manually recalculated. The dashboard was piloted on a single ward by shadow running the dashboard for 6 months. Processes were optimised before hospital-wide implementation. Results The dispense and administration data in the dashboard accurately reflected the registrations in the EHR and all predefined validation criteria were met. Subsequently, the paper process for accounting for CS was successfully digitised, allowing nurses to discontinue the double registration workflow. The CS accountability showed a slight upward trend from 88% prior to implementation to 91% after implementation. Furthermore, use of the dashboard resulted in a more efficient workflow and facilitated evaluation between the pharmacy and the wards, contributing to optimisation of prescribing, administration and the logistical processes. Conclusions The dashboard provided an accurate and reliable reflection of CS-related dispenses and administrations documented in the EHR, supporting its hospital-wide implementation for CS monitoring. The CS accountability dashboard reduced the administrative workload for nurses and the pharmacy and improved traceability.
- 12 May 2026
- Published by BMJ in European Journal of Hospital Pharmacy
Open AccessDigitising controlled substance accountability: implementation and use of a dashboard-based monitoring system in an university hospital
Objectives Opioids are the cornerstone of severe pain management but they have a strong potential for abuse. To mitigate this risk, hospitals are required to track and account for these controlled substances (CS). Despite widespread adoption of electronic medication administration records (eMAR), nurses also performed paper-based registrations for CS. We hypothesised that a validated dashboard combining dispensing and eMAR data could be implemented for CS accountability. This study describes trends in accountability of dispenses through administrations before, during and after implementation of the dashboard that replaced the paper-based process. Furthermore, we describe its application in analysing signalled discrepancies. Methods This implementation study was performed in a university hospital. The dashboard was developed by a multidisciplinary team consisting of hospital pharmacists, pharmacy technicians, nurses and data analysts. Data from 2018 to 2024 were compared in three periods: prior implementation (2018–2019), during implementation (2020–2022) and after implementation (2023–2024) of the dashboard. Monitored CS medications were limited to oral solids. The data for dispenses and administrations were validated against the electronic health record (EHR) and electronic delta calculations were manually recalculated. The dashboard was piloted on a single ward by shadow running the dashboard for 6 months. Processes were optimised before hospital-wide implementation. Results The dispense and administration data in the dashboard accurately reflected the registrations in the EHR and all predefined validation criteria were met. Subsequently, the paper process for accounting for CS was successfully digitised, allowing nurses to discontinue the double registration workflow. The CS accountability showed a slight upward trend from 88% prior to implementation to 91% after implementation. Furthermore, use of the dashboard resulted in a more efficient workflow and facilitated evaluation between the pharmacy and the wards, contributing to optimisation of prescribing, administration and the logistical processes. Conclusions The dashboard provided an accurate and reliable reflection of CS-related dispenses and administrations documented in the EHR, supporting its hospital-wide implementation for CS monitoring. The CS accountability dashboard reduced the administrative workload for nurses and the pharmacy and improved traceability.
- Open Access
- 10 February 2025
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 33 (3) , 206-212
Resolution rate of prescribing errors after advice from a specialised hospital pharmacist or a substitute hospital pharmacist: a retrospective cross-sectional study
Specialised hospital pharmacists, integrated in medical teams on the ward, can improve medication safety. When a specialised hospital pharmacist is temporarily not available, the pharmaceutical care will be conducted by a substitute hospital pharmacist with less specific knowledge about that patient population. Our objective was to compare the resolution rate of prescribing errors between specialised hospital pharmacists and their substitutes. Furthermore, we investigated whether other characteristics of the pharmacists, the prescriber, patient, drug or intervention itself were associated with the resolution rate. A retrospective cross-sectional study was conducted to assess the resolution of prescribing errors, based on the analysis of electronic prescriptions. A prescribing error was defined as an alert that required intervention of the pharmacist to prevent harm or to optimise therapy. To identify prescribing errors, a medical doctor and hospital pharmacist analysed all alerts that were retained to be checked by a pharmacist. Resolution of a prescribing error was defined as resolution of the error within 24 hours after detection. In total, 145 574 medication prescriptions were analysed and 448 prescribing errors were detected. Of these prescribing errors, 94.0% were resolved within 24 hours. No differences were found between the resolution rate of prescribing errors after advice from a specialised hospital pharmacists and their substitutes (94.4% vs 91.9%, p=0145 (χ2 test)). Administrative prescribing errors, prescribing errors for patients aged >80 years and prescribing errors handled during weekends showed a relatively low-resolution rate. No other characteristics of the pharmacist, prescriber, patient, the drug involved or the intervention itself were associated with the resolution of the prescribing error. In the temporarily absence of a specialised hospital pharmacist, the resolution rate of prescribing errors remains high when advice about prescribing errors is provided by a substitute hospital pharmacist.
- 10 February 2025
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 33 (3) , 206-212
Open AccessResolution rate of prescribing errors after advice from a specialised hospital pharmacist or a substitute hospital pharmacist: a retrospective cross-sectional study
Specialised hospital pharmacists, integrated in medical teams on the ward, can improve medication safety. When a specialised hospital pharmacist is temporarily not available, the pharmaceutical care will be conducted by a substitute hospital pharmacist with less specific knowledge about that patient population. Our objective was to compare the resolution rate of prescribing errors between specialised hospital pharmacists and their substitutes. Furthermore, we investigated whether other characteristics of the pharmacists, the prescriber, patient, drug or intervention itself were associated with the resolution rate. A retrospective cross-sectional study was conducted to assess the resolution of prescribing errors, based on the analysis of electronic prescriptions. A prescribing error was defined as an alert that required intervention of the pharmacist to prevent harm or to optimise therapy. To identify prescribing errors, a medical doctor and hospital pharmacist analysed all alerts that were retained to be checked by a pharmacist. Resolution of a prescribing error was defined as resolution of the error within 24 hours after detection. In total, 145 574 medication prescriptions were analysed and 448 prescribing errors were detected. Of these prescribing errors, 94.0% were resolved within 24 hours. No differences were found between the resolution rate of prescribing errors after advice from a specialised hospital pharmacists and their substitutes (94.4% vs 91.9%, p=0145 (χ2 test)). Administrative prescribing errors, prescribing errors for patients aged >80 years and prescribing errors handled during weekends showed a relatively low-resolution rate. No other characteristics of the pharmacist, prescriber, patient, the drug involved or the intervention itself were associated with the resolution of the prescribing error. In the temporarily absence of a specialised hospital pharmacist, the resolution rate of prescribing errors remains high when advice about prescribing errors is provided by a substitute hospital pharmacist.
- Open Access
- 31 January 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1739-1748
Concomitant use of clopidogrel and proton pump inhibitors: A retrospective analysis of prescription behaviour
Aims: Since omeprazole and esomeprazole reduce the effect of clopidogrel on the inhibition of platelet aggregation, concomitant use of these drugs has been discouraged by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) since 2010. Currently, it is unknown how often this undesired drug–drug combination is prescribed. The aim of this article is to determine the proportion of patients using omeprazole or esomeprazole among patients using clopidogrel with gastroprotective drugs and to identify differences between these two groups with regard to patient characteristics and prescriber characteristics. Methods: This was a retrospective analysis of Dutch outpatient medication prescription records between 2015 and 2022. The database had a coverage of approximately 62% of all outpatient prescriptions dispensed in The Netherlands. Results: The proportion of patients using omeprazole or esomeprazole as gastroprotective drug in combination with clopidogrel declined from 19.7% to 8.7% between 2015 and 2022. The undesired drug–drug combination was more often prescribed by internists, to women and to patients with polypharmacy (using >10 drugs). Conclusions: Although the proportion of patients using clopidogrel together with omeprazole or esomeprazole declined between 2015 and 2022, the undesired combination is still frequently prescribed in The Netherlands. Education about this drug–drug interaction for pharmacists and prescribers is needed since pharmacotherapeutic alternatives are available.
- 31 January 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1739-1748
Open AccessConcomitant use of clopidogrel and proton pump inhibitors: A retrospective analysis of prescription behaviour
Aims: Since omeprazole and esomeprazole reduce the effect of clopidogrel on the inhibition of platelet aggregation, concomitant use of these drugs has been discouraged by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) since 2010. Currently, it is unknown how often this undesired drug–drug combination is prescribed. The aim of this article is to determine the proportion of patients using omeprazole or esomeprazole among patients using clopidogrel with gastroprotective drugs and to identify differences between these two groups with regard to patient characteristics and prescriber characteristics. Methods: This was a retrospective analysis of Dutch outpatient medication prescription records between 2015 and 2022. The database had a coverage of approximately 62% of all outpatient prescriptions dispensed in The Netherlands. Results: The proportion of patients using omeprazole or esomeprazole as gastroprotective drug in combination with clopidogrel declined from 19.7% to 8.7% between 2015 and 2022. The undesired drug–drug combination was more often prescribed by internists, to women and to patients with polypharmacy (using >10 drugs). Conclusions: Although the proportion of patients using clopidogrel together with omeprazole or esomeprazole declined between 2015 and 2022, the undesired combination is still frequently prescribed in The Netherlands. Education about this drug–drug interaction for pharmacists and prescribers is needed since pharmacotherapeutic alternatives are available.
- 31 August 2023
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 32 (1) , 41-45
Do junior doctors make more prescribing errors than experienced doctors when prescribing electronically using a computerised physician order entry system combined with a clinical decision support system? A cross-sectional study
Objectives Prescribing errors can lead to inconvenience, morbidity and mortality. It is therefore crucial to educate doctors to prescribe safely, efficiently and effectively. To create an effective educational programme, it is essential to understand which errors are made and by whom. The aim of this study is to explore if the experience level of the doctor influences how many and which prescribing errors are made in a European academic teaching hospital, where a computerised physician order entry system (CPOE) with a clinical decision support system (CDSS) is exclusively used. Methods Prescriptions for all inpatients in an academic teaching hospital were collected in June 2021. All prescriptions with an alert generated by the CDSS which could not be handled by a pharmacy technician according to local protocol were checked for errors. Identified errors were categorised by type and severity. Results A total of 130 538 prescriptions were newly made or altered by doctors. Of these prescriptions, 1914 (1.5%) were retained for a check by the pharmacist. These contained 430 prescribing errors (0.3% of total prescriptions). Doctors not in specialty training and those in specialty training made more prescribing errors than consultants (0.5% and 0.5% vs 0.1%; pConclusions Doctors not in specialty training and doctors in specialty training, who are the less experienced doctors, make more prescribing errors than consultants, even with the use of a CPOE combined with CDSS. The type of errors differ between doctors of different experience levels. This finding provides a solid basis for specific additional education to medical students, doctors not in specialty training and doctors in specialty training.
- 31 August 2023
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 32 (1) , 41-45
Do junior doctors make more prescribing errors than experienced doctors when prescribing electronically using a computerised physician order entry system combined with a clinical decision support system? A cross-sectional study
Objectives Prescribing errors can lead to inconvenience, morbidity and mortality. It is therefore crucial to educate doctors to prescribe safely, efficiently and effectively. To create an effective educational programme, it is essential to understand which errors are made and by whom. The aim of this study is to explore if the experience level of the doctor influences how many and which prescribing errors are made in a European academic teaching hospital, where a computerised physician order entry system (CPOE) with a clinical decision support system (CDSS) is exclusively used. Methods Prescriptions for all inpatients in an academic teaching hospital were collected in June 2021. All prescriptions with an alert generated by the CDSS which could not be handled by a pharmacy technician according to local protocol were checked for errors. Identified errors were categorised by type and severity. Results A total of 130 538 prescriptions were newly made or altered by doctors. Of these prescriptions, 1914 (1.5%) were retained for a check by the pharmacist. These contained 430 prescribing errors (0.3% of total prescriptions). Doctors not in specialty training and those in specialty training made more prescribing errors than consultants (0.5% and 0.5% vs 0.1%; pConclusions Doctors not in specialty training and doctors in specialty training, who are the less experienced doctors, make more prescribing errors than consultants, even with the use of a CPOE combined with CDSS. The type of errors differ between doctors of different experience levels. This finding provides a solid basis for specific additional education to medical students, doctors not in specialty training and doctors in specialty training.
- Open Access
- 22 July 2023
- Published by Elsevier in Patient Education and Counseling
- Vol. 115, 107921
Inpatients’ information needs about medication: A narrative systematic literature review
- 22 July 2023
- Published by Elsevier in Patient Education and Counseling
- Vol. 115, 107921
Open AccessInpatients’ information needs about medication: A narrative systematic literature review
- Open Access
- 8 September 2021
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 44 (1) , 138-145
A cost–benefit analysis of hospital-wide medication reviews: a period prevalence study
Background For specific medical specialties it has been shown that clinical pharmacists can have a beneficial effect on the reduction of drug-related problems by performing medication reviews. However, little is known on the cost–benefit ratio of hospital-wide implementation of medication reviews. Aim To investigate the effect of conducting hospital-wide medication reviews on the detection and resolution of drug-related problems, and to calculate the cost–benefit ratio of the intervention. Method In this observational prospective period prevalence study, medication reviews were conducted during five consecutive working days in a Dutch university hospital. Patients admitted for more than 24 h were included. The cost–benefit ratio of conducting the medication reviews was calculated by dividing the total costs by the total savings. Results In 622 medication reviews, 709 potential drug-related problems (1.1 per patient) were detected. The most common advice was to stop medication (38.6%). Patients with a potentially drug-related problem were significantly older, had a higher median number of prescriptions, and the median number of days from admission to the time of medication reviews was longer. Conducting medication reviews showed a positive cost–benefit ratio of 9.7. Conclusions Hospital-wide medication reviews by clinical pharmacists have a positive cost–benefit ratio and contribute to the detection and the resolution of drug related problems (DRPs), mainly by reducing overtreatment.
- 8 September 2021
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 44 (1) , 138-145
Open AccessA cost–benefit analysis of hospital-wide medication reviews: a period prevalence study
Background For specific medical specialties it has been shown that clinical pharmacists can have a beneficial effect on the reduction of drug-related problems by performing medication reviews. However, little is known on the cost–benefit ratio of hospital-wide implementation of medication reviews. Aim To investigate the effect of conducting hospital-wide medication reviews on the detection and resolution of drug-related problems, and to calculate the cost–benefit ratio of the intervention. Method In this observational prospective period prevalence study, medication reviews were conducted during five consecutive working days in a Dutch university hospital. Patients admitted for more than 24 h were included. The cost–benefit ratio of conducting the medication reviews was calculated by dividing the total costs by the total savings. Results In 622 medication reviews, 709 potential drug-related problems (1.1 per patient) were detected. The most common advice was to stop medication (38.6%). Patients with a potentially drug-related problem were significantly older, had a higher median number of prescriptions, and the median number of days from admission to the time of medication reviews was longer. Conducting medication reviews showed a positive cost–benefit ratio of 9.7. Conclusions Hospital-wide medication reviews by clinical pharmacists have a positive cost–benefit ratio and contribute to the detection and the resolution of drug related problems (DRPs), mainly by reducing overtreatment.
- Open Access
- 13 August 2013
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 22 (3) , 231-233
Important information regarding reporting of adverse drug reactions: a qualitative study
To give an overview of the views of different types of reporters (patients and healthcare professionals (HCPs)) and assessors of adverse drug reactions (ADRs) on what they consider important information regarding an ADR report. A semi-structured interview was conducted among reporters and assessors of ADRs in the Netherlands. All interviews were audiotaped and transcribed verbatim. Content analysis was used on the data. All transcripts were coded individually by two researchers. A list was drafted of all elements of information mentioned during the interviews. In total 16 interviews were conducted. Elements of information that were explicitly brought up during the interviews were the impact of the ADR on the patient's daily life and information regarding causality. Furthermore, the correctness of reported information was found important by assessors of ADRs. Generally, patient reporting was seen as a very positive development for pharmacovigilance. Patients reported that the severity of ADRs and their impact on daily life were important subjects. In the interviews with HCPs, either reporters or assessors, the focus was mainly on causality. The correctness of the given information is considered by ADR assessors to be very important. Regarding patient reporting the overall view was positive. Because HCPs and patients have different views regarding ADR reporting, in daily practice it is important to receive reports from both groups to assess the true nature of the ADR.
- 13 August 2013
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 22 (3) , 231-233
Open AccessImportant information regarding reporting of adverse drug reactions: a qualitative study
To give an overview of the views of different types of reporters (patients and healthcare professionals (HCPs)) and assessors of adverse drug reactions (ADRs) on what they consider important information regarding an ADR report. A semi-structured interview was conducted among reporters and assessors of ADRs in the Netherlands. All interviews were audiotaped and transcribed verbatim. Content analysis was used on the data. All transcripts were coded individually by two researchers. A list was drafted of all elements of information mentioned during the interviews. In total 16 interviews were conducted. Elements of information that were explicitly brought up during the interviews were the impact of the ADR on the patient's daily life and information regarding causality. Furthermore, the correctness of reported information was found important by assessors of ADRs. Generally, patient reporting was seen as a very positive development for pharmacovigilance. Patients reported that the severity of ADRs and their impact on daily life were important subjects. In the interviews with HCPs, either reporters or assessors, the focus was mainly on causality. The correctness of the given information is considered by ADR assessors to be very important. Regarding patient reporting the overall view was positive. Because HCPs and patients have different views regarding ADR reporting, in daily practice it is important to receive reports from both groups to assess the true nature of the ADR.